While some NENs, such as melanoma and non-small cell lung cancer (NSCLC), have shown promising outcomes in terms of PD-1/PD-L1 expression and ICIs, some malignancies, such as Merkel cell carcinoma (MCC), require further clinical trial data to better advise IO management [166]. This evidence concerns the gene CD274 and Merkel cell skin cancer.